CAMBRIDGE, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call and audio webcast on Thursday, November 3, 2016, at 8:30 a.m. Eastern Time to report recent company highlights and third quarter 2016 financial results.

To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 96812020. The webcast can be accessed under "Events and Presentations" in the Investor Center section of the company's website at

About Epizyme, Inc. Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients. Epizyme has built a proprietary product platform that the Company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients. For more information, visit
Contacts:Media:Julie DiCarlo, Epizyme, Inc.(617) 306-5823jdicarlo@epizyme.comInvestors:Monique Allaire, THRUST

Primary Logo